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Abstract
Increased catabolism of arginine by arginase is increasingly viewed as an important pathophysiological factor in
cardiovascular disease, including atherosclerosis induced by high cholesterol diets. Whereas previous studies have focused
primarily on effects of high cholesterol diets on arginase expression and arginine metabolism in specific blood vessels, there
is no information regarding the impact of lipid diets on arginase activity or arginine bioavailability at a systemic level. We,
therefore, evaluated the effects of high fat (HF) and high fat-high cholesterol (HC) diets on arginase activity in plasma and
tissues and on global arginine bioavailability (defined as the ratio of plasma arginine to ornithine + citrulline) in apoE2/2
and wild-type C57BL/6J mice. HC and HF diets led to reduced global arginine bioavailability in both strains. The HC diet
resulted in significantly elevated plasma arginase in both strains, but the HF diet increased plasma arginase only in apoE2/2
mice. Elevated plasma arginase activity correlated closely with increased alanine aminotransferase levels, indicating that
liver damage was primarily responsible for elevated plasma arginase. The HC diet, which promotes atherogenesis, also
resulted in increased arginase activity and expression of the type II isozyme of arginase in multiple tissues of apoE2/2 mice
only. These results raise the possibility that systemic changes in arginase activity and global arginine bioavailability may be
contributing factors in the initiation and/or progression of cardiovascular disease.
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Arginine metabolism plays important roles in vascular function
in health and disease. The key enzymes involved in arginine
metabolism in the vasculature are the nitric oxide synthases and
the arginases, both of which use arginine as a substrate [1], and
dysregulated activity or expression of these enzymes has been
linked to multiple types of endothelial dysfunction and cardiovas-
cular disease [2–5]. Because diet is one of the major modifiable
risk factors for cardiovascular disease, there is considerable interest
in characterizing the impact of high-risk diets on changes in
arginine metabolism that are associated with cardiovascular
disease.
One example of cardiovascular disease that involves dysregu-
lated arginine metabolism and also is strongly influenced by diet is
atherosclerosis. Stages of atherogenesis, more specifically endo-
thelial dysfunction, have been strongly related to dysregulated
nitric oxide (NO) synthesis [6]. Nitric oxide production by the
enzyme nitric oxide synthase in the vascular endothelium requires
the substrate L-arginine. Thus, L- arginine supports antiathero-
genic effects mostly mediated by nitric oxide. However, L-
arginine is also catabolized by arginase to ornithine and urea.
Arginase, induced in response to inflammatory stimuli in a variety
of cell types [7–9], consists of two isozymes (types I and II), and
there is increasing evidence that arginase is a biologically relevant
modulator of vascular structure and function. In models of
endothelial dysfunction as a consequence of aging, ischemia-
reperfusion or hypertension, vascular arginase has been shown to
be elevated [10–16]. Both arginase inhibition and arginine
supplementation restore vascular function and nitric oxide
production, indicating a role of substrate limitation by arginase
for endothelial nitric oxide synthase [10–13,15,16]. Furthermore,
in vitro studies have shown that arginine metabolism via arginase in
vascular smooth muscle cells increased downstream polyamine
and proline synthesis, resulting in increased proliferation and
collagen synthesis [17–19]. Therefore, increased arginase can
contribute to vascular disease by both reducing available arginine
for NO synthesis and enhancing vascular remodeling. The roles
and regulation of arginase activity and systemic L-arginine
metabolism during initiation and progression of cardiovascular
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diseases, such as atherosclerosis, are not well understood. More
specifically, the effects of diets with varying lipid and cholesterol
content on systemic arginase activity and global arginine
bioavailability have not been evaluated.
We hypothesized that high fat diets—with and without high
cholesterol—would cause systemic disruption of arginine metab-
olism through increased arginase activity. We also hypothesized
that a high fat-high cholesterol diet that leads to atherosclerosis in
an animal model would result in changes in arginine metabolism
or arginase expression beyond that resulting from a high fat diet
alone. To test these hypotheses, apoE2/2 mice, genetically prone
to develop atherosclerosis [20], and C57BL/6 mice, the wild type
controls, were fed a standard chow diet, a high fat-high cholesterol
(1.25%) diet containing cholate (HC), known as a highly
atherogenic diet [21], and a high fat (HF) diet with moderate
cholesterol (0.2%), associated with obesity rather than with
atherosclerosis [22]. We evaluated plasma arginase activity,
plasma lipids and amino acids, plasma levels of liver enzymes,
and arginine/(ornithine + citrulline) ratio, an indicator of global
arginine bioavailability [23,24]. The activities and expression of
the arginases also were evaluated in multiple tissues.
Results
Effects of diets on plasma enzyme activities and plasma
lipids
Most studies of the effects of diets in apoE2/2 mice have
focused tightly on development and progression of atherosclerotic
plaques. However, the HC diet used here and in many other
studies also induces inflammatory responses in the liver [25–28],
raising the possibility that liver damage might result in elevated
plasma levels of arginase I and thus reduce circulating arginine
levels. Thus, plasma arginase activities were determined for three
independent experiments in which C57BL6 and apoE2/2 mice
were fed standard, HF or HC diets for 2 months as described in
Methods. Because the HC diet differed from the standard chow
diet with regard to both fat and cholesterol content, the HF diet
was included to differentiate any effects of increased fat content
alone. Whereas plasma arginase activities did not differ signifi-
cantly for C57BL6 and apoE2/2 mice on the standard chow diet,
there were strain-specific differences in responses to the HF and
HC diets (Figure 1). Plasma arginase activities were increased
equally in apoE2/2 mice on HF and HC diets. Although there
was a trend toward increased plasma arginase activity in C57BL6
mice on the HF diet, it was not statistically significant. However,
there was a dramatic increase in plasma arginase activity in
C57BL6 mice fed the HC diet, to a level nearly twice as high as
the elevated plasma arginase activity in apoE2/2 mice fed the HF
or HC diet (Figure 1).
As significant diet- and strain-specific differences in plasma
arginase activities were found, more detailed biochemical and
molecular studies were performed for a representative experiment
in which samples of multiple tissues also had been collected. All
subsequent data are from that experiment. On all diets, the
apoE2/2 mice had significantly higher plasma cholesterol levels as
compared to C57BL/6J. Whereas the HF diet had no effect on
plasma cholesterol, the HC diet induced marked increases in both
strains (Figure 2). Plasma triglycerides were significantly reduced
by the HC diet in both strains but were not affected by the HF diet
in either strain. No changes in blood urea nitrogen were observed
in any of the groups, indicating no loss of renal function (data not
shown). However, plasma alanine aminotransferase (ALT) levels
were significantly increased by the HC diet in both strains but by
the HF diet only in the apoE2/2 mice (Figure 3). Elevated plasma
ALT levels have been shown previously for C57BL/6J mice fed
the HC diet [25,26]. The elevated ALT levels are indicative of
liver damage, consistent with previous studies showing liver
inflammation and injury associated with high cholesterol-high fat
diets in mice [25–30]. Notably, the profile of plasma ALT levels
closely parallels the profile of plasma arginase activities in Figure 1.
For example, plasma ALT and arginase activities are significantly
correlated for apoE2/2 mice on the three diets (Figure 4), even
though apoE2/2 mice on the HC diet differ significantly from
apoE2/2 mice on the standard and HF diets with regard to
arginase expression in nonhepatic tissues (discussed below).
Because the liver is the greatest source of arginase in the body,
the association between the increases in plasma arginase activities
and ALT levels indicates that liver damage represents the principal
source of increased arginase activity.
Effects of diets on arginine bioavailability
Plasma levels of arginine, ornithine and citrulline were not
significantly affected by any diet in C57BL/6J mice (Table 1). In
the apoE2/2 mice, however, a reduction in circulating arginine
levels was found only with the HC diet. There was also a trend for
reduced plasma arginine in apoE2/2 mice on the HF diet, but this
did not reach statistical significance (p = 0.06; Table 1). Plasma
ornithine was significantly increased only in the apoE2/2 mice on
the HF diet. There were no diet- or strain-specific differences in
plasma citrulline levels, suggesting no difference in activity of the
intestinal-renal axis of citrulline/arginine metabolism [1]. Overall,
there was no consistent pattern of dietary lipid effect on plasma
levels of these individual amino acids.
Consideration of the plasma levels of these individual amino
acids may fail to reveal significant changes in arginine metabolism
because it overlooks the fact that they are metabolically
interrelated [1]. Consequently, the ratio of plasma arginine to
the sum of plasma ornithine plus citrulline has been developed as
an indicator of global arginine bioavailability that is more sensitive
to perturbations in arginine metabolism than are levels of the
individual amino acids [23,24]. Unlike the values of individual
amino acids, this ratio clearly revealed effects of the diets: global
arginine bioavailability was significantly reduced in C57BL6 fed
the HC diet and apoE2/2 mice fed the HF or HC diet (Figure 5).
The groups with reduced global arginine bioavailability also
exhibited increases in plasma arginase activity and liver enzymes
(Figures. 1 and 3).
Effects of diet on tissue arginase activity and expression
In contrast to the changes in the plasma, arginase activities in
tissues were increased only in the apoE2/2 mice fed the HC diet
(Figure 6), the group with the highest plasma cholesterol levels. No
increases were observed in apoE2/2 mice fed the HF diet or in
any of the C57BL/6J groups (data not shown). Increased arginase
activity was observed in the heart, lung, kidney and spleen of
apoE2/2 mice fed the HC diet (Figure 6). The high levels of liver
arginase activity did not differ significantly between strains and
were not altered by any of the experimental conditions (e.g.,
apoE2/2 mice: 35846507 nmol/mg/min; standard diet vs
39586324 nmol/mg/min; HC diet), consistent with the fact that
hepatic levels of arginase and the other urea cycle enzymes are
responsive primarily to changes in the intake and catabolism of
protein [31–33].
As arginase activity represents the sum of contributions by
arginases I and II, levels of arginase mRNAs and protein were
evaluated. Increased arginase activity was accompanied by
increased arginase II mRNA in heart, lung, spleen and kidney
of apoE2/2 mice fed the HC diet (Figure 7A). Only the heart had
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significantly increased arginase I mRNA. Increased arginase
activity and arginase II mRNA in lung, spleen, and kidney were
accompanied by increased levels of arginase II protein (Figure 7B
and D). Arginase I protein was increased in extracts from spleen
(Figure 7C and D) but was below the level of detection in Western
blots of lung and kidney extracts. Thus, arginase II was primarily
Figure 1. Effect of HF and HC diets on plasma arginase activity (nmol/ml/min). Values are means 6 SE for n = 10-15 for standard and HC
diet and n = 6 for HF diet. Key to symbols: apoE2/2 (open bars); C57BL/6J (black bars); *p,0.05 vs standard diet; $p,0.05 vs strain-specific HF diet.
doi:10.1371/journal.pone.0015253.g001
Figure 2. Effect of HF and HC diets on plasma triglycerides and cholesterol. Values are means 6 SE for n = 5 mice in each group. Key to
symbols: apoE2/2 (open bars); C57BL/6J (black bars); *p,0.05 vs strain specific standard diet; $p,0.05 vs strain-specific HF diet; #p,0.05 for apoE2/2
vs C57BL/6J fed same diet.
doi:10.1371/journal.pone.0015253.g002
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responsible for the overall arginase activity in lung and kidney
whereas both isoforms contributed to overall activity in spleen.
Discussion
Although previous studies have implicated elevated arginase
activity and expression in atherogenesis (reviewed in [2,3,34]),
results of the present investigation demonstrate that an ‘‘athero-
genic diet’’ can result in more widespread alterations in arginase
activity and arginine metabolism than has previously been
recognized. Major new findings of this study include demonstra-
tions that the HC diet led to markedly elevated circulating
arginase activity and reduced arginine bioavailability in both wild-
type and apoE2/2 mice, and these changes occurred also in the
apoE2/2 mice on the high fat diet. So far as we are aware, effects
of high fat or high cholesterol diets on plasma arginase and global
arginine bioavailability have not been evaluated in any previous
studies. The elevation of plasma arginase activity correlated closely
with increased plasma ALT levels, indicating that damage of the
liver, which contains the greatest amount of arginase in the body,
was primarily responsible for the elevated plasma arginase. If
plasma arginase were derived significantly from tissues other than
liver, it is probable that plasma values for ALT and arginase in
apoE2/2 mice on the HC diet—the only condition in which
arginase activity was significantly elevated in multiple tissues—
would not correlate with plasma values for ALT and arginase in
apoE2/2 mice on the HF diet. With the exception of a single
outlier, however, the correlation was strong across all diet groups
(Figure 4). Increased plasma arginase following liver injury has
been well-documented by other investigators [35–38]. Although
reductions in global arginine bioavailability in this study were
Figure 3. Effect of HF and HC diets on plasma levels of ALT. Values are means 6 SE for n = 5 mice in each group. Symbols are defined in
Figure 2 legend.
doi:10.1371/journal.pone.0015253.g003
Figure 4. Correlation between activities of ALT and arginase in
plasma of apoE2/2 mice on different diets. Regression analysis of
ALT and arginase activities for the different diets (n = 5 in each group) is
indicated by the solid line. Key to symbols: solid circles, standard diet;
solid diamonds, HF diet; open circles, HC diet.
doi:10.1371/journal.pone.0015253.g004
Table 1. Effect of diet on plasma amino acid levels (mM) in
C57BL/6J and apoE2/2 mice.
Mouse strain and Diet Arginine Ornithine Citrulline
C57BL6 Standard diet 115638 71626 76622
C57BL6 HF Diet 9164 6667 6963
C57BL6 HC Diet 85619 85611 9268
apoE2/2 Standard diet 10066 6164 6562
apoE2/2 HF Diet 8267 8567* 7662
apoE2/2 HC Diet 73610* 62610 7669
n = 4 for HF groups and n = 3 for all other groups. Values are means 6 SE.
*p,0.05 vs strain-specific standard diet.
doi:10.1371/journal.pone.0015253.t001
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consistently associated with elevations in plasma arginase activity
rather than with increases in tissue arginase activity, this does not
rule out the possibility that increased tissue arginase activity may
additionally result in localized reductions in arginine availability
that may impact vascular or tissue function.
Reductions in global arginine bioavailability are associated with
cardiovascular complications and have been shown to be an
independent risk factor for morbidity and mortality in humans
[23,24]. In sickle cell patients, reduced global arginine bioavail-
ability is associated with pulmonary arterial hypertension [23],
which leads to right ventricular hypertrophy that likely contributes
to the increased mortality in this patient population. In non-sickle
cell patients, reductions in global arginine bioavailability are
associated with development of obstructive atherosclerotic coro-
nary artery disease and increased incidence of major adverse
cardiovascular events [24]. Taken together, these findings raise the
possibility that diet-induced reductions in global arginine bioavail-
ability alone may increase risk for developing some types of
cardiovascular/endothelial dysfunction that may not be readily
apparent except perhaps at longer time periods of dietary
treatment, even in animal models that do not develop significant
atherosclerotic plaques within a few months (e.g., mice fed HF
diets).
As noted previously, mice fed the HC diet exhibit an
accelerated rate of atherosclerotic development and hepatic
inflammation that is correlated with increased plasma cholester-
ol. Interestingly, the HF diet did not raise plasma cholesterol
levels but did result in liver injury in the apoE2/2 mice, as
indicated by the elevated plasma arginase and ALT activities, but
not in the C57BL/6J strain. In contrast to the HC diet, however,
the HF diet did not lead to increased arginase activity in tissues of
apoE2/2 mice.
Figure 5. HF and HC diets reduce global arginine bioavailability. Values are means 6 SE for n = 3–4 in each group. Abbreviations: ARG,
arginine; ORN, ornithine; CIT, citrulline. Symbols are defined in Figure 2 legend.
doi:10.1371/journal.pone.0015253.g005
Figure 6. Induction of tissue arginase activities in apoE2/2 mice on HC diet. Values are means 6 SE for n = 6 in each group. *p,0.05 vs
standard diet.
doi:10.1371/journal.pone.0015253.g006
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Although both C57BL/6J and apoE2/2 mice maintained on
the HC diet, which results in accelerated plaque development
[21,39,40], exhibited increases in plasma arginase and reductions
in global arginine bioavailability, the apoE2/2 mice fed the HC
diet were the only animals with increases in tissue arginase activity
and expression. Although C57BL/6J mice on the HC diet also had
cholesterol levels that were significantly increased, previous studies
have shown that the HC diet does not induce significant atheroma
formation within the two-month time frame used in this study
[21,41]. It is therefore of particular interest that apoE2/2 mice fed
the same percentage cholesterol as the HC diet used in our study
had reduced plaque development when the apoE2/2 mutation
was expressed in a mouse strain that completely lacks expression of
arginase II [34]. The fact that multiple tissues in the apoE2/2
mice fed the HC diet had increased arginase activity and
expression suggests that an atherogenic diet, via increased arginase
expression, may have a broader impact on vascular and organ
function than has previously been appreciated.
The fact that tissue arginase was elevated only in apoE2/2 mice
on the HC diet raises the possibility that the mechanism(s)
underlying increased arginase expression also may be part of the
inflammatory process leading to atherosclerosis. It is known that
arginase is increased in response to a variety of inflammatory
stimuli [3,7–9], but the precise stimuli involved in arginase
induction under atherogenic conditions have not been identified.
Since activation of liver X receptors by cholesterol metabolites has
been shown to induce expression of the arginase II gene [42], it is
possible that cholesterol metabolites may themselves play a direct
role in inducing arginase II expression in tissues of apoE2/2 mice
fed the HC diet.
In summary, these findings demonstrate for the first time that
increased plasma arginase activity and widespread tissue expres-
sion of arginase II–together with reductions in global arginine
bioavailability–are associated with a diet that induces atherogen-
esis in apoE2/2 mice. Further studies are warranted to elucidate
the possible roles of increased circulating arginase, reduced global
Figure 7. Induction of arginase mRNA and protein in apoE2/2 mice on HC diet. (A) Effect of HC diet on arginase I and II mRNAs in heart,
lung, spleen and kidney. mRNA levels are expressed relative to the levels in apoE2/2 mice on standard diet (arbitrarily set to 1.0 for each tissue and
indicated by dotted line). Values are means 6 SE for n = 5–7 in each group. *p,0.05 vs standard diet. (B) Effect of HC diet on arginase II protein
abundance in lung, spleen and kidney. For each tissue, the upper panel represents arginase II and the lower panel GAPDH. Western blots of extracts
from tissues of 5 representative animals on each diet are shown. Amounts of protein loaded in each lane were 10 mg (lung and kidney) or 25 mg
(spleen). An extract of C57BL/6J whole kidney (20 mg for lung and kidney blots, 3 mg for spleen blot) was used in the first lane of each blot as positive
control (+CT) for arginase II. Twenty mg protein from kidney of the arginase II knockout mouse [47] was included in the second lane of the kidney blot
in order to establish identity of the lowest band as arginase II. (C) Effect of HC diet on arginase I protein abundance in spleen. The upper panel
represents arginase I and the lower panel GAPDH. The Western blot represents extracts from spleen (50 mg each lane) of 5 representative animals on
each diet and 100 ng of C57BL/6J liver extract (+CT) as positive control. (D) Densitometry of Western blots, represented in arbitrary units (Arginase/
GAPDH), was analyzed by Image Quant 5.2 Software. *p,0.01 vs standard diet. Molecular weights are indicated by the following symbols: solid
triangles, 39 kDa; solid diamonds, 37 kDa; open triangles, 37 kDa.
doi:10.1371/journal.pone.0015253.g007
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arginine bioavailability, and elevated tissue arginase activity in
vascular dysfunction, as well as to identify the specific cells in
tissues in which arginase expression was increased and to elucidate
their impact on vascular function.
Methods
Experimental Design
Male C57BL/6J and B6.129P2-Apoetm1Unc (apoE2/2 mice)
(Jackson Laboratory, Bar Harbor, ME) aged 6–7 weeks were used
in this study. All mice were provided water ad libitum in ventilated
cages in a controlled humidity and temperature environment with
a 12hr light/dark cycle. Animal care and use procedures were
conducted in accordance with the ‘‘PHS Policy on Human Care
and Use of Laboratory Animals’’ and the ‘‘Guide for the Care and
Use of Laboratory Animals’’ (NIH publication 86–23, 1996).
These procedures were approved by the National Institute for
Occupational Safety and Health Institutional Animal Care and
Use Committee (internal approved protocol ID 07-PS-M-014). In
three independent experiments, different groups of mice were
placed on one of the following diets for 2 months: 1) standard
chow diet (Harlan 7913 irradiated NIH-31 6% rodent diet
containing protein, 186 g/Kg; fat, 62.5 g/Kg; fiber, 45.3 g/Kg;
metabolizable energy, 3.13 Kcal/g; 18% total kcal from fat;
0.053% cholesterol), 2) high fat and high cholesterol diet
containing cholate (HC; TD88051 Harlan; 37.1% total kcal from
fat; 1.25% cholesterol; 0.5% sodium cholate) [43] and 3) high fat
diet (HF; D12451 Research Diets; 45% total kcal from fat; 0.20%
cholesterol) [44]. Prior to sacrifice and collection of blood mice
were fasted 16 hr. Following CO2 asphyxiation blood was
collected from vena cava followed by perfusion with cold PBS
via the heart. For one group of experimental animals in which
responses to all 3 diets were evaluated, tissues also were harvested,
quick frozen in liquid nitrogen and stored at 280uC for arginase
activity and RNA isolation.
Plasma Chemistry
In initial experiments we found that plasma from some samples
of whole blood that had been placed on ice for a couple of hours
prior to fractionation had remarkably low arginine (,20 mM) and
high ornithine levels (.150 mM) that were not representative of
values in plasma that was rapidly fractionated and frozen. Thus,
EDTA blood samples were immediately centrifuged, and plasma was
quick-frozen and stored at 280uC until used for analysis. Plasma
levels of total cholesterol, triglycerides, blood urea nitrogen and
ALT were analyzed (AniLytics Inc.). A complete plasma amino
acid profile was determined by the Medical Genetics Laboratory
at Baylor College of Medicine.
Arginase Activity
For arginase activity, tissue homogenates were prepared using
the TissueLyser (Qiagen) in 0.1% Triton X-100 with 2 mM
Pefabloc (Roche), 2 mg/ml pepstatin A (Sigma) and 10 mg/ml
leupeptin (Sigma). Samples were placed on ice for 10 minutes then
centrifuged at 12,000 g for 10 minutes and supernatants were
used. Arginase activity in plasma and tissue homogenates was
determined as the conversion of [14C-guanidino]-L-arginine
(American Radiolabeled Chemicals or Moravek) to [14C]urea
(2.5-hr incubation for plasma and all tissues except liver – 1/50
dilution for 30 min), which was then converted to 14CO2 by urease
and trapped as Na2
14CO3 and counted on a scintillation counter
as described previously [8]. Protein concentrations were deter-
mined by the BCA protein assay kit (Pierce) and used to calculate
arginase specific activities. Plasma arginase activity was expressed
as activity per volume plasma (nmol/ml/min).
Real-time RT-PCR
Real-time RT-PCR was performed as previously described
[45]. Briefly, RNA was isolated using the RNeasy Mini Kit
(Qiagen) according to manufacturer’s directions. One mg of total
RNA was reverse transcribed using random hexamers (Applied
Biosystems) and Superscript III (Invitrogen). Five ml of cDNA (in
duplicate for each gene) was then used for mRNA determinations.
Pre-designed Assays-on-DemandTM TaqManH gene expression
assays (Applied Biosystems) for arginase I and arginase II were
used. Ribosomal 18S RNA and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) mRNA were used as internal references
for normalization. Relative gene expression was calculated using
the comparative threshold method (22DDCt) [46]. There was no
difference in relative fold change compared to reference using
either 18S rRNA or GAPDH mRNA.
Western Blot
Using methods described previously [45], Western blotting was
performed on the tissue homogenates used for assays of arginase
activity. Western blots were developed with antibody to arginase I
(BD Transduction Laboratories #610708;1:1000 dilution in 1%
nonfat milk/1%BSA/Tris-buffered saline containing 0.1% Tween
20 (TBS-T)), antibody to arginase II (Santa Cruz Biotechnology
#sc-20151; 1:500 dilution in 5% nonfat milk in TBS-T) and
secondary HRP-linked antibodies (1:5000) from GE Healthcare.
Following immunodetection of arginase, blots were stripped
(Pierce Restore Plus Western Blot Stripping Buffer) and re-probed
with antibody to GAPDH (Santa Cruz Biotechnology #sc-25778;
1:2000 dilution in 5% milk/TBS-T) to verify equal protein
loading. There were insufficient amounts of heart extract to
analyze by Western blot.
Statistics
All data are presented as mean 6 standard error. Analyses were
performed using JMPH Statistical Discovery Software utilizing
analysis of variance with a least squares means table generated by
a student’s t-test post-hoc test. In data sets where there was no
homogeneity of variance, values were log transformed prior to
analysis. Student’s t-test was used only when two groups of equal
sample size were compared. Differences were considered statisti-
cally significant at p,0.05.
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